In order to increase efficacy and sustainability of TKI treatment, IFN-α has been combined with imatinib in multiple clinical trials, such as the German CML-Study IV [51] and French ST157I Prospective Randomized Trial (SPIRIT) [52], reviewed by Talpaz et al. [53]. This evidence concerns the gene IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive.